This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

These have recently been revised. Co-trimoxazole is now licensed for the treatment of urinary tract infections and acute exacerbations of chronic bronchitis but only where there is bacterial evidence of sensitivity to co-trimoxazole and good reason to prefer the combination to a single antibiotic. The circumstances where 'good reason' applies where not defined by the licensing authority.

In children, co-trimoxazole is licensed for the treatment of acute otitis media in children where there is good reason to prefer co-trimoxazole to a single antibiotic.

Co-trimoxazole is the first line treatment for pneumocystis carinii. The drug is also licensed for the treatment and prevention of toxoplasmosis and the treatment of nocardiasis.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.